PTSD and DNA Methylation in Select Immune Function Gene Promoter Regions: A Repeated Measures Case-Control Study of U.S. Military Service Members by Jennifer A. Rusiecki et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSYCHIATRY
ORIGINAL RESEARCH ARTICLE
published: 24 June 2013
doi: 10.3389/fpsyt.2013.00056
PTSD and DNA methylation in select immune function
gene promoter regions: a repeated measures case-control
study of U.S. military service members
Jennifer A. Rusiecki 1*, Celia Byrne1, Zygmunt Galdzicki 2,Vasantha Srikantan1, Ligong Chen1,
Matthew Poulin3, LiyingYan3 and Andrea Baccarelli 4
1 Department of Preventive Medicine, School of Medicine, Uniformed Services University, Bethesda, MD, USA
2 Department of Anatomy, Physiology and Genetics, School of Medicine, Uniformed Services University, Bethesda, MD, USA
3 EpigenDx Inc., Worcester, MA, USA
4 Exposure, Epidemiology and Risk Program, Harvard School of Public Health, Harvard University, Boston, MA, USA
Edited by:
Tania L. Roth, University of Delaware,
USA
Reviewed by:
Elisabeth B. Binder, Max Planck
Institute of Psychiatry, Germany
Ulrike Ehlert, University of Zurich,
Switzerland
*Correspondence:
Jennifer A. Rusiecki , Department of
Preventive Medicine and Biometrics,
School of Medicine, Uniformed
Services University, 4301 Jones
Bridge Road, Room E-2009,
Bethesda, MD 20814, USA
e-mail: jennifer.rusiecki@usuhs.edu
Background: The underlying molecular mechanisms of PTSD are largely unknown. Dis-
tinct expression signatures for PTSD have been found, in particular for immune activation
transcripts. DNA methylation may be significant in the pathophysiology of PTSD, since the
process is intrinsically linked to gene expression. We evaluated temporal changes in DNA
methylation in select promoter regions of immune system-related genes in U.S. military
service members with a PTSD diagnosis, pre- and post-diagnosis, and in controls.
Methods: Cases (n=75) had a post-deployment diagnosis of PTSD in their medical record.
Controls (n=75) were randomly selected service members with no PTSD diagnosis. DNA
was extracted from pre- and post-deployment sera. DNA methylation (%5-mC) was quan-
tified at specific CpG sites in promoter regions of insulin-like growth factor 2 (IGF2), long
non-coding RNA transcript H19, interleukin-8 (IL8), IL16, and IL18 via pyrosequencing. We
used multivariate analysis of variance and generalized linear models to calculate adjusted
means (adjusted for age, gender, and race) to make temporal comparisons of %5-mC for
cases (pre- to post-deployment) versus controls (pre- to post-deployment).
Results: There were significant differences in the change of %5-mC pre- to post-
deployment between cases and controls for H19 (cases: +0.57%, controls: −1.97%;
p=0.04) and IL18 (cases: +1.39%, controls: −3.83%; p=0.01). For H19 the difference
was driven by a significant reduction in %5-mC among controls; for IL18 the difference
was driven by both a reduction in %5-mC among controls and an increase in %5-mC
among cases. Stratified analyses revealed more pronounced differences in the adjusted
means of pre-post H19 and IL18 methylation differences for cases versus controls among
older service members, males, service members of white race, and those with shorter
deployments (6–12 months).
Conclusion: In the study of deployed personnel, those who did not develop PTSD had
reduced %5-mC levels of H19 and IL18 after deployment, while those who did develop
PTSD had increased levels of IL18. Additionally, pre-deployment the people who later
became cases had lower levels of IL18 %5-mC compared with controls. These findings
are preliminary and should be investigated in larger studies.
Keywords: post-traumatic stress disorder, DNA methylation, cytokines, inflammation, promoter region, Operation
Iraqi Freedom, Operation Enduring Freedom, epigenetics
INTRODUCTION
Estimates of post-deployment PTSD prevalence in U.S. military
service members who served in Afghanistan and Iraq are 12 and
18%, respectively (Hoge et al., 2004); a recent study reported aver-
ages of 10–20% (Thomas et al., 2010). Despite these high rates
among military populations, as well as high rates in civilian pop-
ulations [i.e., U.S. prevalence rates of 7–8% (Kessler et al., 1994,
1997); lifetime prevalence of 9–14% (Kessler et al., 1995; Breslau,
2001)], the underlying molecular mechanisms of PTSD are largely
unknown.
Given the sustained stress of the sympathetic nervous system
and resulting hyper-arousal state in PTSD, it has been hypoth-
esized that immune system functioning is affected. A series of
recent studies has shown that PTSD is associated with alterations
in immune function (Hoge et al., 2009) in particular increased lev-
els of some canonical pro-inflammatory cytokines (Spivak et al.,
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1997; Maes et al., 1999; Sutherland et al., 2003; von Kanel et al.,
2007) and decreased levels of anti-inflammatory cytokines (Kawa-
mura et al., 2001; von Kanel et al., 2007; Smith et al., 2011).
Profiling using cDNA microarrays of peripheral blood during
the triggering and development of PTSD in trauma survivors at
the emergency room and 4 months later has found differential
gene expression signatures in promoter regions of genes which
distinguished PTSD patients (Segman et al., 2005; Zieker et al.,
2007). Distinct expression signatures were found in particular for
transcripts involved in immune activation (Segman et al., 2005).
Up-regulated genes included insulin-like growth factor 2 (IGF2)
and pro-inflammatory/neuroprotective chemokine, IL8 (CXCL8);
down-regulated genes included the pro-inflammatory pleiotropic
cytokines, interleukin 16 (IL16), and interleukin 18 (IL18) (Seg-
man et al., 2005; Zieker et al., 2007). Similar findings of differential
expression of genes involved in immune cell function were found
among cases of PTSD from the World Trade Center attack ver-
sus controls (Sarapas et al., 2011) and in a study of Bosnian war
refugees with PTSD versus controls (Nowotny et al., 2010).
An epigenetic mechanism, DNA methylation may play a sig-
nificant role in the pathophysiology of PTSD, since the process is
intrinsically linked to gene regulation. Recently, epigenetic mech-
anisms, including regulation of chromatin structure and DNA
methylation, have been found to be regulators of gene transcrip-
tion in the CNS (Zovkic and Sweatt, 2013). Methylation changes
may completely silence a gene or may decrease or increase gene
expression. It is hypothesized that epigenetic molecular mecha-
nisms, especially DNA methylation/demethylation, may influence
long-term behavioral change through active regulation of gene
transcription in the CNS. A recent review proposed that epigenetic
molecular mechanisms underlie the formation and stabilization
of context- and cue-triggered fear conditioning based in the hip-
pocampus and amygdala, a conclusion reached in a wide variety
of studies using laboratory animals (Zovkic and Sweatt, 2013).
In humans, there is a small, but growing body of literature that
supports a potential link between DNA methylation of immune
function genes and PTSD. A recent study applying methylation
microarrays to assay CpG sites in peripheral blood from PTSD
cases and controls found differential methylation in genes related
to immune system functions (Uddin et al., 2010). In particular,
this study found that IL8, a gene that regulates innate and adaptive
immune system processes, was unmethylated among PTSD cases
(Uddin et al., 2010). Another recent study in an African Amer-
ican population found that psychosocial stress may alter global
and gene-specific DNA methylation patterns potentially associated
with peripheral immune dysregulation (Smith et al., 2011).
In the present study, we focused on a set of growth fac-
tors/transcripts and cytokines/chemokines previously implicated
in PTSD: paternally imprinted IGF2, maternally imprinted H19 (a
long, non-coding RNA transcript), IL8, IL16, and IL18 (Segman
et al., 2005; Zieker et al., 2007; Nowotny et al., 2010; Uddin et al.,
2010; Sarapas et al., 2011; Smith et al., 2011). We evaluated pro-
moter region methylation levels as percentage of 5-methyl cytosine
(%5-mC) in DNA from serum of PTSD cases and controls, who
were U.S. military soldiers who deployed to Afghanistan [Opera-
tion Enduring Freedom (OEF)] or Iraq [Operation Iraqi Freedom
(OIF)] between 2004 and 2006. Our study had the unique ability to
investigate temporal changes in methylation patterns after deploy-
ment [a proxy for exposure to a potentially traumatic event (PTE)].
The pre- and post-deployment samples collected in our study
enable such evaluations of temporal changes in methylation pat-
ters. Our objectives were to investigate DNA methylation patterns
associated with PTSD.
Since human studies of brain tissue are highly invasive, identify-
ing a low-invasive biomarker of epigenetic patterns of PTSD would
be of great clinical value. Most of the studies to date which have
measured expression signatures or methylation patterns in PTSD
or other psychiatric disorders have been carried out using periph-
eral blood (Segman et al., 2005; Zieker et al., 2007; Nowotny et al.,
2010; Uddin et al., 2010; Sarapas et al., 2011; Smith et al., 2011).
To our knowledge, serum has not yet been evaluated for gene-
specific methylation patterns potentially associated with PTSD.
Serum and cerebrospinal fluid (CSF) have been found to have
good correlation with respect to cytokine gene expression, and in
this exploratory study we evaluated DNA methylation from serum
as a biomarker, without drawing links to other types of tissues
or directly extrapolating its significance. Serum DNA methylation
patterns may provide a surrogate indicator of differential response
to stress and vulnerability to PTSD. Unlike previous studies, we
had unique access to biologic samples prior to onset of disease
and prior to deployment (a proxy for exposure to a PTE). Serum
samples from military service members have been stored at the
Department of Defense Serum Repository (DoDSR) since the
early 1990’s. We were able to access those stored sera and iden-
tified samples drawn prior to and post-deployment for all cases
and controls.
MATERIALS AND METHODS
STUDY POPULATION
The study population has been described previously (Rusiecki
et al., 2012). The target population was male and female U.S.
Army and Marines service members serving their first OEF/OIF
deployment between January 01, 2004 and December 31, 2006.
Deployment length was between 6 and 18 months. Via query of
medical records using the International Classification of Diseases,
Ninth Revision (ICD-9) codes 290–320, we determined an absence
of any mental health diagnoses dating back to at least 2 years
prior to first OEF/OIF deployment for all cases and controls. In
an effort to exclude possible confounding by other psychiatric
illnesses, for which differential gene expression or methylation
has been reported (Mill and Petronis, 2007; Shimabukuro et al.,
2007; Tamura et al., 2007; Kuratomi et al., 2008; Feng and Fan,
2009; Iwamoto and Kato, 2009; Gavin and Sharma, 2010) post-
deployment exclusion criteria for both cases and controls was ever
having a health encounter for schizophrenia (ICD-9 code 295),
bi-polar disorders (ICD-9 code 296), and manic phase bi-polar
disorder (also ICD-9 code 296).
The PTSD cases (n= 75) had existing pre- and post-
deployment serum samples housed at the DoDSR, met all the
criteria above, and had at least two outpatient records with a pri-
mary diagnosis of chronic PTSD, based on ICD-9 Code 309.81
in the first diagnostic position. The first outpatient diagnosis was
between 4 and 12 months after return from first deployment. The
second outpatient diagnosis was any time after that, but within
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2 years of return from first deployment. Additional criteria for
inclusion as a case to this study was having one serum sample
(the pre-deployment sample) drawn within 12 months prior to
first OEF/OIF deployment and one sample (the post-deployment
sample) drawn within 6 months after return from first OEF/OIF
deployment. Cases were randomly selected within each gender,
such that 25 females and 50 males were included. We identified an
appropriate active duty service member control group (n= 75),
who were frequency matched from a stratified, random sample
based on age (20–26, 27–35), gender, and race, but for whom there
was never a diagnosis of PTSD (ICD-9 Code= 309.81) or Trau-
matic Brain Injury (TBI) (ICD-9 Codes= 800.0–801.9, 803.0–
804.9, or 850.0–854.1). Though cases in this study are presumed
to have experienced a PTE by virtue of their PTSD diagnosis, the
criteria of which requires exposure to a PTE, we have no data on
formal assessment of trauma/PTE for either cases or controls. As
such, this study uses deployment as a proxy for exposure to a PTE
for both cases and controls. Because of Department of Defense
policy regarding the DoDSR samples, we were unable to make con-
tact with the study subjects for whom we had serum and medical
encounter data.
SAMPLE PREPARATION AND LABORATORY METHODS
DNA extraction
For each PTSD case and control, The Armed Forces Health Surveil-
lance Center identified a pre-deployment and a post-deployment
serum sample and authorized release of up to 0.5 ml of serum per
sample. These samples had been maintained at −30 °C contin-
uously at the DoDSR. DNA was extracted using ChargeSwitch ®
gDNA 0.2–1 ml serum kit from (Invitrogen Carlsbad, CA, USA)
and quantified via Qubit ® dsDNA HS Assay Kit using a Qubit
fluorometer (Invitrogen, Carlsbad, CA, USA).
Quantification of DNA methylation
DNA methylation was quantified via bisulfite treatment, PCR, and
pyrosequencing. DNA was bisulfite treated using the Zymo DNA
Methylation Kit (Zymo research, Orange, CA, USA). All assays
used in this study were validated by PCR bias testing and sensitiv-
ity testing. This was done to assess the lowest input gDNA needed
for bisulfite modification and the lowest input bisulfite converted
DNA for PCR for each assay. For H19, IL8, IL16, and IL18, a mini-
mum of 40 ng of DNA was used for bisulfite conversion. For IGF2,
a minimum of 10 ng DNA was used for bisulfite conversion. The
total DNA available for each sample was used as input gDNA for
bisulfite conversion. Carrier RNA from Qiagen was used during
the bisulfite modification and purification to minimize the loss of
DNA during the procedure. Bisulfite treated DNA was eluted in
20µl volume and 1µl of it was used for each PCR. The PCR (45
cycles) was performed with one of the PCR primers biotinylated to
convert the PCR product to single-stranded DNA templates. The
PCR products (each 10µl) were sequenced by Pyrosequencing
PSQ96 HS System (Qiagen Pyrosequencing) following the manu-
facturer’s instructions (Qiagen Pyrosequencing). Pyrosequencing
is a real-time sequencing-based on mutation analysis or methy-
lation analysis technology. The methylation status of each CpG
locus was analyzed individually as a T/C SNP using QCpG software
(Qiagen Pyrosequencing).
The loci of specific CpGs measured in each promoter region
are shown in Figure 1 and the rationale for selecting these spe-
cific loci was that they are generally located in the shore/vicinity
of transcriptional start site. Loci measured were in the promoter
regions of H19 [-1964, -1946, -1927, -1919 from the transcrip-
tional H19 start site (TSS)], IGF2 [TSS-479, -476, -460, -361, -341,
-322; note, the investigated regions for IGF2 covered the promoter
of IGF2, p2, and the binding region for enhancer-blocking ele-
ment CCCTC-binding factor (CTCF) upstream of the H19 start
site], IL8 (TSS-116, -106, -31), IL16 (TSS-159, -139, -93, -79), and
IL18 (TSS-158, -108, -86, -49, -33). The percentage of methylation
(%5-mC) was expressed as 5-mC divided by the sum of methylated
and unmethylated cytosine. This is interpreted as the percentage
of cytosines at a given CpG site (or position) which is methy-
lated. Percent 5-mC was measured at each CpG site, hereafter
referred to as position, and a mean %5-mC was calculated across
all positions measured in a promoter region. Starting from bisulfite
modification, four controls [low, medium, high methylated DNA
(EpigenDx, Inc.), and a no DNA template] were included in every
pyrosequencing run to ensure specificity of PCR amplification,
and success of pyrosequencing reactions.
DNA from cases and controls were randomly arranged on the
plates for methylation quantification analysis. For 10% of the sam-
ples we included duplicates to which laboratory personnel were
blinded, for the purpose of quality control (QC). Coefficients of
variation as well as intraclass correlation coefficients (ICCs) were
calculated for the means of each position in H19 (CV= 0.05,
ICC= 0.75; p< 0.01), IL8 (CV= 0.01, ICC= 0.72; p< 0.01),
IL16 (CV= 0.05, ICC= 0.68; p< 0.01), and IL18 (CV= 0.02,
ICC= 0.89; p< 0.01). The duplicate samples were run on a sepa-
rate plate from their counterparts, and some of the variation could
be due to a plate effect.
Approximately 30% of the samples (N = 86) had DNA yields
(e.g., <40 ng) insufficient for bisulfite conversion of H19, IL8,
IL16, and IL18. Approximately 5% of the samples (N = 15) had
DNA yields (e.g., <10 ng) insufficient for bisulfite conversion of
IGF2. These samples were excluded from our study. For a small
percentage of the samples for which bisulfite conversion was com-
plete, pyrosequencing signals were too low to be reliable (0% for
H19, 9% for IGF2, 0.05% for IL8, 8% for IL16, and 2% for IL18),
thus we did not include them in our final analyses. It is unclear
why signals were low for those particular samples, however, low
signals were not associated with DNA yield. Distribution of sam-
ples either not measured or measured but with low signals did not
differ by pre- and post-deployment or case/control status, with the
exception of IGF2 pre-deployment case/control status. However,
this is likely because there were only 16 with low signals for that
assay, thus lending to the instability of those proportions.
Statistical methods
Our statistical analyses considered %5-mC in the promoter and/or
known methylation region of each gene at each position (CpG
site) measured as well as the mean of all the positions mea-
sured. We compared the change in cases’ %5-mC from pre- to
post-deployment, to the change in controls’ %5-mC from pre-
to post-deployment using multivariate ANOVA. We present the
adjusted mean of pre-post methylation difference for cases versus
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FIGURE 1 | Loci of specific CpGs measured in IGF2, H19, IL8, IL16, and IL18.
controls, adjusted for age, gender, and race. To further investi-
gate the adjusted means and differences between cases and con-
trols, pre-deployment and post-deployment, we ran generalized
linear models (GLMs) Using GLMs, we carried out case-case
and control-control (i.e., pre- to post-deployment) comparisons,
as well as case-control comparisons, pre-deployment, and post-
deployment. We carried out the same analyses, stratifying by age,
gender, race, and length of deployment, separately, to investigate
any potential patterns within specific groups. SAS Version 9.2 was
used to carry out all statistical analyses. The SAS procedures GLM
and ANOVA were used to run our final models (SAS Institute Inc.,
2008).
This study was approved by the Institutional Review Board at
the Uniformed Services University of the Health Sciences.
RESULTS
Baseline characteristics of the study population are in Table 1.
Although the study was designed with 75 cases and 75 controls,
we excluded 2 study subjects (1 case/1 control) because their
DNA yield was insufficient for DNA methylation quantification
for any of the loci measured in both pre- and post-deployment
time frames. The remaining 148 study subjects did not neces-
sarily have complete data for all loci measured in both pre- and
post-deployment time frames, but they did have DNA methyla-
tion quantified for at least one locus in at least one time frame.
The study population did not differ by case-control status for age,
gender, and race because of the selection and frequency match-
ing criteria. Approximately 73% of cases and 76% of controls had
deployments of 6 months to less than 12 months, while 27% of
cases and 24% of controls had deployments of 12–18 months.
These small differences were not statistically significant. The num-
ber of days between end of deployment and post-deployment
serum draw ranged from 1 to 170 (mean= 22.45; SD= 38.84;
median= 7), and the number of days between pre-deployment
serum draw and start of deployment ranged from 58 to 358
(mean= 87.46; SD= 84.49; median= 58.5). There were no dif-
ferences between cases and controls for these time intervals, nor
were there differences by occupational code or rank/rate. There
were four cases who also had a post-deployment diagnosis of
TBI (defined as an ICD-9 code of 800.0–801.9, 803.0–804.9, or
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Table 1 | Baseline characteristics of population.
Characteristic Cases (N =74) Controls (N =74) p-Value
N % N %
AGE
Younger (20–23 years) 40 54.1 38 51.4 0.74
Older (24–35 years) 34 46.0 36 48.7
GENDER
Male 49 66.2 49 66.2 1.00
Female 25 33.8 25 33.8
RACE
White 59 79.7 60 81.1 0.84
Black 15 20.3 14 18.9
DEPLOY LENGTH
Short (6 to <12 months) 54 73.0 56 75.7 0.71
Long (12–18 months) 20 27.0 18 24.3
TIME BETWEEN DEPLOYMENT END AND POST-DEPLOYMENT SERUM SAMPLE DRAW
≤7 days 41 55.4 38 51.4 0.62
>7 days 33 44.6 48 48.6
TIME BETWEEN PRE-DEPLOYMENT SERUM DRAW AND DEPLOYMENT START
≤90 days 52 70.3 45 60.8 0.23
>90 days 22 29.7 29 39.2
OCCUPATIONAL CODING*
Less likely involved in combat 19 38.8 20 38.5 0.97
More likely involved in combat 30 61.2 32 61.5
Missing 25 22
RANK/RATE#
Junior enlisted 57 77.0 52 70.3 0.35
Middle-grade/senior enlisted and officer 17 23.0 22 29.7
*Based on military occupational specialty POC coding as either less likely to be involved in combat or more likely to be involved in combat.
#Junior enlisted included E-2 through E-4; middle/senior enlisted and officer included E-5 through E-8, O-1 through O-3, and W-2.
850.0–854.1) (data not shown). We carried out all analyses includ-
ing and excluding those four cases to evaluate potential confound-
ing by TBI and found that results were very similar. We, therefore,
present all results for analyses including those four PTSD cases
with concurrent TBI.
Table 2 presents the results of a multivariate ANOVA com-
paring adjusted means of pre-post methylation differences for
cases versus controls. These results show that, accounting for the
exposure of deployment (i.e., proxy for PTE), there were signif-
icant reductions in %5-mC for controls, compared with cases at
H19 (mean of positions 1–4: cases: +0.57%, controls: −1.97%;
p= 0.04) and IL18 (mean of positions 1–5: cases: +1.39%, con-
trols −3.83%; p= 0.01). Position 3 in H19 and positions 4 and 5
in IL18 had statistically significant differences between cases and
controls, and though differences in the change of methylation were
not significant at other positions for H19 and IL18, they all showed
similar patterns.
Table S1 in Supplementary Material provides additional detail
on the change in methylation across deployment for cases and con-
trols; paired differences in adjusted mean levels for cases pre- and
post-deployment and controls pre- and post-deployment, deter-
mined via GLM, are presented. The differences between cases and
controls across deployment for H19 were driven primarily by the
significant reduction in %5-mC among controls from pre- to post-
deployment (the levels for cases were unchanged across deploy-
ment for H19). The pattern of decreased H19 methylation among
controls from pre- to post-deployment is evident; statistically sig-
nificant decreases were found at positions 1, 3, and 4, and for
the mean of positions 1–4. The differences for IL18 were dri-
ven by both the decrease in methylation across deployment for
controls as well as the increase in methylation across deployment
for cases. There was a pattern of decreased methylation among
controls from pre- to post-deployment, though a statistically sig-
nificant decrease was found for position 5 only. There was also
a pattern of increased IL18 methylation for cases pre- to post-
deployment, though none of the comparisons was statistically
significant.
Table S2 in Supplementary Material, which presents case-
control comparisons for both pre- and post-deployment, further
illustrates that for IL18, %5-mC was lower in cases compared with
controls, pre-deployment (p≤ 0.05 for positions 2, 4, and 5, and
the mean of the five positions), while the pattern reversed post-
deployment, such that levels were non-statistically significantly
higher in cases compared with controls. Note that the term “case”
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Table 2 | Multivariate ANOVA comparing adjusted* mean of pre-post
methylation difference between cases and controls.
Gene promoter Npairs1 Mean2 SE p-Value
H19 (mean positions 1–4) Case 37 0.57 1.10 0.04
Control 45 −1.97 0.99
Position 1; TSS-1964 Case 37 0.58 1.30 0.09
Control 45 −1.92 1.16
Position 2; TSS-1946 Case 37 1.38 1.41 0.14
Control 45 −1.01 1.26
Position 3; TSS-1926 Case 37 0.65 1.15 0.01
Control 45 −2.93 1.03
Position 4; TSS-1919 Case 37 −0.33 1.44 0.31
Control 45 −2.01 1.29
IGF2 (mean positions 1–6) Case 52 −2.61 3.25 0.81
Control 62 −3.49 3.01
Position 1; TSS-479 Case 52 −0.22 4.77 0.76
Control 62 −1.83 4.42
Position 2; TSS-476 Case 52 −2.97 4.94 0.59
Control 62 0.00 4.58
Position 3; TSS-460 Case 52 4.16 4.93 0.40
Control 62 −0.52 4.57
Position 4; TSS-361 Case 52 −12.14 4.59 0.67
Control 62 −9.98 4.32
Position 5; TSS-341 Case 52 −2.79 3.97 0.84
Control 62 −3.71 3.74
Position 6; TSS-322 Case 52 −2.90 3.37 0.95
Control 62 −3.13 3.17
IL8 (mean of positions 1–3) Case 36 −0.17 0.32 0.25
Control 44 −0.58 0.28
Position 1; TSS-116 Case 36 −0.54 0.54 0.38
Control 44 −1.06 0.47
Position 2; TSS-106 Case 36 −0.12 0.46 0.36
Control 44 −0.58 0.40
Position 3; TSS-31 Case 36 0.15 0.17 0.20
Control 44 −0.10 0.15
IL16 (mean of positions 1–4) Case 31 −4.23 3.66 0.88
Control 38 −3.61 3.66
Position 1; TSS-159 Case 31 −5.61 4.80 0.97
Control 38 −5.44 4.78
Position 2; TSS-139 Case 31 −2.94 3.34 0.89
Control 38 −3.44 3.33
Position 3; TSS-93 Case 31 −4.29 6.58 0.95
Control 38 −4.76 6.64
Position 4; TSS-79 Case 31 −5.00 6.22 0.85
Control 38 −3.78 6.27
IL18 (mean of positions 1–5) Case 37 1.39 1.85 0.01
Control 45 −3.83 1.66
Position 1; TSS-158 Case 37 −2.60 2.66 0.50
Control 45 −4.63 2.40
Position 2; TSS-108 Case 37 2.31 2.31 0.03
Control 45 −3.50 2.08
(Continued)
Gene promoter Npairs1 Mean2 SE p-Value
Position 3; TSS-86 Case 37 1.88 2.47 0.21
Control 45 −1.66 2.22
Position 4; TSS-49 Case 37 2.35 1.93 0.01
Control 45 −3.43 1.75
Position 5; TSS-33 Case 37 2.13 2.23 0.02
Control 45 −4.03 2.02
*Adjusted for age, gender, race.
1Pairs of samples, i.e., pre and post paired samples among the cases and among
the controls – number of pairs differ for the different promoter regions measured
because of sensitivity of each assay – i.e., some samples were dropped because
of low pyrosequencing signals for a specific assay.
2Adjusted mean of the difference from pre- to post-deployment for cases and for
controls.
in the pre-deployment context refers to people who later became
cases, post-deployment; during the pre-deployment time period,
they were not yet cases.
Also shown in Table S2 in Supplementary Material are a few
other loci where significant differences in %5-mC were found
between cases and controls pre-deployment, i.e., IGF2 position
2 (%5-mCcases >%5-mC controls, p= 0.01) and IL8 position 2
(%5-mCcases <%5-mC controls, p= 0.01). There were no signifi-
cant differences in adjusted mean levels for the post-deployment
case-control comparisons.
Stratified analyses (Table 3) revealed more pronounced differ-
ences in the adjusted means of pre-post H19 and IL18 methylation
differences for cases versus controls among older (24–35 years)
service members (H19 position 3 case/control: +0.13/−3.66;
p= 0.05), males (H19 position 3 case/control: +0.80/−2.99;
p= 0.01; IL18 mean case/control: +0.47/−5.38), service mem-
bers of white race (H19 mean case/control:+0.72/−2.70; p= 0.01;
IL18 mean case/control: +2.82/−2.16; p= 0.04), and those
with deployments between 6 and 12 months (H19 position 3
case/control: +0.16/−3.20; p= 0.02; IL18 mean case/control:
+2.52/−4.65; p= 0.01).
DISCUSSION
Our study found that there were significant differences in the
change of methylation (%5-mC) across deployment between cases
and controls for H19 and IL18. While there was no change in %5-
mC in H19 for cases from pre- to post-deployment, there was a
significant decrease among controls driving the difference in %5-
mC change between the cases and controls. For IL18 there was
a significant difference between the %5-mC decrease in controls
and the %5-mC increase in cases, from pre- to post-deployment.
These findings were more pronounced in both H19 and IL18 in
younger service members, males, service members of white race,
and those with shorter deployment length. There were a few addi-
tional statistically significant findings at specific CpG sites, such
as pre-deployment case-control differences in IGF2 position 2
and in IL8 position 2. Given the low signals from the IGF2 assay
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Table 3 | Multivariate ANOVA comparing adjusted* mean of pre-post methylation difference for cases versus controls, stratified by age, gender,
race, and deployment length.
Gene promoter/CpG site Subject Age: younger (20–23) and older (24–35)
Younger Older
N µ p-Value N µ p-Value
H19 position 3 Case 20 0.71 0.11 17 0.13 0.05
Cont 25 −2.47 20 −3.66
H19 mean of positions Case 20 0.34 0.36 17 0.58 0.07
Cont 25 −1.34 20 −3.00
IL18 mean of positions Case 20 0.60 0.22 17 1.38 0.05
Cont 25 −3.94 20 −3.07
Gender: female and male
Female Male
N µ p-Value N µ p-Value
H19 position 3 Case 9 0.59 0.24 28 0.80 0.01
Cont 16 −2.74 29 −2.99
H19 mean of positions Case 9 0.98 0.12 28 0.91 0.14
Cont 16 −2.84 29 −1.27
IL18 mean of positions Case 9 1.12 0.35 28 0.47 0.03
Cont 16 −1.80 29 −5.38
Race: black and white
Black White
N µ p-Value N µ p-Value
H19 position 3 Case 6 −0.65 0.43 31 1.64 0.01
Cont 8 −3.07 37 −2.30
H19 mean of positions Case 6 −0.95 0.73 31 0.72 0.01
Cont 8 0.14 37 −2.70
IL18 mean of positions Case 6 −0.31 0.21 31 2.82 0.04
Cont 8 −5.53 37 −2.16
Deployment length: long (6 to <12) and short (12–18)
Long Depl. Short Depl.
N µ p-Value N µ p-Value
H19 position 3 Case 8 4.20 0.42 29 0.16 0.02
Cont 11 0.75 34 −3.20
H19 mean of positions Case 8 3.56 0.38 29 0.12 0.12
Cont 11 0.68 34 −2.14
IL18 mean of positions Case 8 −2.08 0.93 29 2.52 0.01
Cont 11 −2.46 34 −4.65
*For analyses stratified on age, adjusted for gender and race; for analyses stratified on gender, adjusted for age and race; for analyses stratified on race, adjusted for
age and gender; for analyses stratified on deployment length, adjusted for age, gender, and race.
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being differentially distributed between pre-deployment cases and
controls, we are cautious to interpret the results for IGF2. Whether
these patterns represent markers of vulnerability or resiliency is
speculative. Psychological stress incurred during deployment may
be associated with a methylation response in these genes, but given
the lack of PTE data for controls, this study is not able to address
whether the response is protective of PTSD or puts one at risk
for PTSD.
The most consistent result from our study, which is detailed in
Table S2 in Supplementary Material, is that cases pre-deployment
had significantly lower %5-mC in the IL18 promoter region than
controls pre-deployment. This difference was found at positions
2, 4, and 5, and the mean of all five positions; p-values approached
significance for positions 1 (0.08) and 3 (0.06). There was a rever-
sal of this pattern post-deployment, in that cases had higher levels
at all positions, compared to controls, though differences were
not statistically significant. Given that DNA methylation is often
inversely correlated with gene expression, in particular for immune
system-related genes (Oliveira et al., 2009) these results for IL18 are
generally consistent with findings from a previous study based on
cDNA microarray investigation, which reported down-regulation
of IL18 in PTSD cases (Segman et al., 2005). Interestingly, pro-
inflammatory cytokine IL18, a key mediator of inflammation and
immune response inducing interferon-γ (IFN-γ), is expressed in
the brain and plays a significant role in a number of neuropatho-
logical disorders (Bossu et al., 2010; Anderson and Rodriguez,
2011). IL18 has been recently shown to attenuate breaks in the
blood-brain barrier via IFN-γ independent pathway, suggesting
its potential neuroprotective role (Jung et al., 2012). Our results of
increased IL18 methylation in cases would imply down-regulation
of the gene,which is consistent with previous findings (Zieker et al.,
2007).
Our findings also suggest a potential role of H19 in stress
response (23). The imprinted IGF2-H19 locus (CTCF binding
cite) encodes the growth promoting hormone IGF2 and a long
non-coding RNA H19. The maternally inherited locus transcribes
untranslated H19 RNA, which plays the role of a trans-regulator
of the imprinted gene network controlling embryonic growth and
was recently shown to be processed into micro-RNA (miRNA)-675
(Cunningham et al., 2010; Keniry et al., 2012). Expression of both
genes is partially regulated by a 3′ distal enhancer, and methylation
of the CTCF binding site on the paternal chromosome prevents
binding of the CTCF insulator allowing for activation of the IGF2
promoter. Lack of methylation of the CTCF binding site on the
maternal chromosome, however, prevents IGF2 promoter activa-
tion (Fu et al., 2004; Cunningham et al., 2010; Keniry et al., 2012).
Although a previous study reported that IGF2 was up-regulated
in the whole blood (Zieker et al., 2007) IGF2-mediated signal-
ing has been implicated in fear extinction and was proposed as a
therapeutic venue to attenuate excessive fear memory potentially
via promotion of neuronal survival and/or self-renewal of neural
stem cells through its interaction with the insulin receptor (Agis-
Balboa et al., 2011; Ziegler et al., 2012). This could suggest that it is
not only IGF2 that may play a direct role in PTSD fear extinction,
but H19 may be involved in the regulation of IGF2. Also, H19 or
its miRNA products and inhibition of their putative targets may
contribute to the stress response (23).
Previously, we investigated DNA methylation in repetitive ele-
ments, LINE-1 and Alu, in this population and found differ-
ential methylation between pre- and post-deployment controls
and in cases versus controls, post-deployment. In the current
study, we selected specific cytokine promoter regions of interest
based on previous findings in the literature of differential gene
expression or methylation of those cytokines between PTSD cases
and controls (Segman et al., 2005; Zieker et al., 2007; Nowotny
et al., 2010; Uddin et al., 2010; Sarapas et al., 2011; Smith et al.,
2011). Increasing evidence for contribution by the chemokine
network (Semple et al., 2010) and the known role of IGF2 (Torres-
Aleman, 2010) in brain and vasculature development indicates
it as an important target due to possible pre-morbid conditions.
The neuro-chemokine IL8 has been implicated in brain devel-
opment, neuroinflammation, and synaptic transmission (Rostene
et al., 2011). Cytokine IL16, a chemo-attractant for immune
cells expressing surface CD4 molecules (e.g., T-cells) (Cruikshank
and Little, 2008) targets a number of neurophysiological mem-
brane proteins, such as immediate-early gene c-Fos, potassium
and calcium channels, N -Methyl-d-aspartate (NMDA)-receptor
subunits, and neuronal phosphatases through its PDZ domain
and exerts its autocrine function in the brain with a distinct
role in neuropoiesis (Kurschner and Yuzaki, 1999; Schwab et al.,
2001; Bannert et al., 2003). Chemokine IL8 and pro-inflammatory
cytokine IL18 are known to induce inflammatory mediator inter-
feron γ and have been found to play neuroprotective roles in
models of neurodegenerative conditions (Ryu et al., 2010; Semple
et al., 2010).
Only a handful of recent studies have evaluated gene-specific
DNA methylation and PTSD (Uddin et al., 2010, 2011; Ressler
et al., 2011; Trollope et al., 2012) to our knowledge, and these stud-
ies have used only post-PTE blood samples. A cross sectional study
of PTSD-affected and -unaffected individuals enrolled in a longi-
tudinal study which investigated methylation and immune func-
tion profiles in DNA derived from whole blood in a methylation
microarray reported that immune system functions were signif-
icantly overrepresented among the genes uniquely unmethylated
in those with PTSD (Uddin et al., 2010). This signature included
IL8, a gene which regulates innate and adaptive immune system
processes (Uddin et al., 2010). There is emerging evidence that
chemokines like IL8 and its receptors not only regulate immune
cell infiltration but also contribute to a variety of physiological
functions underlying neurotransmission, neuro-protection, and
neurogenesis (Rostene et al., 2011) and therefore may exert a
neuro-modulatory role by changing the balance of neurotrans-
mitters and affecting fear memory (Herry et al., 2008; Joels et al.,
2008). However, a peripheral blood mononuclear cell (PBMC)
gene expression profile carried out in trauma survivors found that
IL8 was under-expressed in PTSD cases, which would indicate
the potential for hypermethylation of IL8 in these cases (Segman
et al., 2005). Another recent human study found that persons who
experienced traumatic events were at increased risk for PTSD, but
only those with lower methylation levels of a serotonin transporter
gene, SLC6A4. At higher methylation levels, individuals with more
traumatic events were protected from PTSD (Koenen et al., 2011).
Our study did not find a post-deployment case-control difference
in this gene. We did find a pre-deployment case-control difference
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in one position in IL8 (position 2) in that people who later became
cases (pre-deployment cases) had lower levels of IL8 than did
controls. This could indicate susceptibility to a PTE or to the devel-
opment of PTSD, however we found it in only one position in the
promoter region.
Serum has not previously been evaluated as a biomarker for
DNA methylation patterns in cytokine gene promoter regions
associated with PTSD. Most of the human studies which have
investigated DNA methylation in PTSD have utilized predom-
inantly whole blood-derived DNA (Uddin et al., 2010, 2011;
Koenen et al., 2011; Ressler et al., 2011; Trollope et al., 2012).
How correlated DNA methylation levels are in serum and whole
blood to brain and other CNS tissues is not clear. However, it
has been reported that some cytokines, such as IL18 can cross
the blood-brain barrier (Alboni et al., 2010; Jung et al., 2012).
The origin of circulating nucleic acids such as cell-free circulating
DNA (cfcDNA) has been hypothesized to stem from necrosis or
apoptosis (Gormally et al., 2007) though others report the pos-
sibility of an active release from cells (Anker et al., 1999; Stroun
et al., 2001; Goebel et al., 2005; Rhodes et al., 2006). Excessive
stress may induce DNA damage in the form of oxidized nucleo-
sides, strand breaks, apoptosis, and necrosis and may be a source
of cfcDNA in serum (Atamaniuk et al., 2011). Additionally, in the
CNS, severe life stress leads to oxidative stress, and the accumu-
lation of reactive oxygen species (ROS) is known to increase the
susceptibility of brain tissue to damage (Schiavone et al., 2013).
ROS, in turn, may also trigger molecular cascades leading to the
blood-brain barrier permeability and neuronal death (Gu et al.,
2011). Compared with cultured cells, clinical specimens, such as
whole blood, serum, and even brain tissue and other CNS tissues,
contain a heterogeneous mixture of cell types, each contributing its
own unique methylation profile to the final analysis. Indeed DNA
methylation patterns have been found to differ globally or locally,
depending on the brain region/sub-region of focus (Iwamoto and
Kato, 2009). One study demonstrated that the human cerebral
cortex has an epigenetic signature distinct from the cerebellum
(Ladd-Acosta et al., 2007) while others have shown that global
DNA methylation differs across sub-regions of the rat hippocam-
pus (Miller and Sweatt, 2007; Brown et al., 2008). These results
taken collectively indicate that even different cortical cells are
likely to have distinct epigenomic patterns. Serum DNA methy-
lation patterns may provide a surrogate indicator of differential
response to stress and PTSD, and our intent was to evaluate it as
a non-invasive biomarker without drawing links to other types
of tissues or directly extrapolating its significance. We evaluated
difference in storage time of serum as a potential factor which
may have influenced DNA methylation patterns. All samples for
this study were obtained from the DoD Serum Repository in June
2009, and DNA was extracted from them soon thereafter. The
time frame of serum being collected from our study subjects,
based on the study sample criteria, was approximately January
2003 through June 2007. We found that cases and controls did not
differ, either pre-deployment or post-deployment with respect to
storage time. The mean storage time for cases pre-deployment was
4.5 years, for controls it was 4.8 years (p= 0.15). The mean storage
time for cases post-deployment was 3.3 years, for controls it was
3.7 years (p= 0.14). As we expected, the storage time did differ
by pre- and post-deployment time period. Thus for cases pre-
deployment the mean was 4.5 years, while post-deployment it was
3.4 years (p=< 0.01). Likewise, the mean storage time for con-
trols pre-deployment was 4.9 years, while post-deployment it was
3.7 (p< 0.01). Based on these differences, we adjusted all our mod-
els in which we carried out a pre/post comparison (i.e., Table 2;
Table S1 in Supplementary Material) by storage time. However,
after adjusting our models for difference in storage time between
pre- and post-deployment samples (for both cases and controls),
there were no changes in our adjusted means and p-values, so we
opted for a more parsimonious model which did not include this
variable.
Limitations of this study include lack of detailed information
on deployment exposures for both the cases and controls. Deploy-
ment was used as a proxy for a PTE, and the exact timing of a
PTE, if it occurred, is not known. There is also the issue that cases,
by virtue of their PTSD diagnosis, were presumably exposed to a
PTE, while we do not know the same for controls. In an attempt
to investigate a possible bias from this disparity, we re-ran all our
analyses utilizing a control group comprised only of those likely
involved in combat during deployment (the group specified in
Table 1 as “more likely involved in combat”). The methylation
patterns we found did not differ from those using the complete
control group (data not shown). We also tried to control for poten-
tial differences in deployment experience by ensuring that all cases
and controls had not been previously deployed, that they were all
active duty Army or Marines, and that they were deployed from
6 to 18 months, but there is still potential for significant variation
among all our subjects with respect to intensity of combat during
deployment. We do not have any data on previous exposure to a
PTE or underlying personality traits, which have been hypothe-
sized to influence vulnerability to PTSD (van Zuiden et al., 2011).
Military personnel, prior to deployment, undergo a medical exam
and are required to complete a pre-deployment health assessment
survey (Department of Defense form 2795) to ensure medical
readiness for deployment. This would have applied to all subjects
in our study.
The timing of sample collection was not standardized, so there
was heterogeneity in the length of time between deployment and
serum draw. Although we tried to minimize this interval, the tim-
ing of each serum sample being added to the DoDSR depended
on the timing of HIV testing for each military service member.
We do not have data on other relevant exposures which may influ-
ence DNA methylation, such as dietary factors (folate, vitamin B12
intake) (Fenech, 2001; Piyathilake and Johanning, 2002) smoking
(Toh et al., 2010), and alcohol consumption (Seitz and Stickel,
2007; Toh et al., 2010; Zhu et al., 2012).
Ascertainment of PTSD via query of ICD-9 coded medical
encounter is not ideal. Although we attempted to restrict the
definition of PTSD to a scenario which would minimize misclassi-
fication of disease, by requiring the ICD-9 code 309.81 be present
in the first diagnostic position for two outpatient records spaced
at a reasonable calendar time distance, this type of case ascertain-
ment is still prone to misclassification. However, this is the PTSD
case definition developed in September 2008 by the Department of
Defense Interagency PTSD and TBI Standardization Committee,
and it has been accepted by Military Health Affairs for surveillance
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(Armed Forces Health Surveillance Center, 2011). The DNA yields
from the sera in this study were small, another potential limitation.
The limitations mentioned above are offset by the rare access to
both pre- and post-deployment biologic samples in cases and con-
trols. While most case-control studies would not be able to infer
whether the observed methylation patterns were a consequence of
PTSD or whether they indicated vulnerabilities that existed among
the cases before the onset of PTSD, our study was able to address
both possibilities. Another strength of the study is that we uti-
lized pyrosequencing to provide a quantitative measure of DNA
methylation. Pyrosequencing is a quantitative real-time sequenc-
ing technology. The light output or the Pyrosequencing signals
(represent as Relative Light Unit or RLU) are directly proportional
to the number of molecules being sequenced. Pyrosequencing
QCpG software has a number of quality assessments to pass or
to fail results for each sample being sequenced. These specifica-
tions give information including sample quality, non-specific PCR
amplification, non-specific sequencing, and completion of bisul-
fite modification. Therefore, if a pyrosequencing run on a specific
sample gave a passing result, it indicates that the DNA of that
sample is of sufficient quality.
Chance could account for some of the statistically significant
findings we report, given the number of comparisons and the small
sample size, but this was an exploratory study and the results
should be considered as preliminary. The DoDSR, which con-
tains over 45 million longitudinally collected serum samples of
U.S. military service members will provide a vast resource for
carrying out future investigations in larger populations. There is
growing evidence that the molecular mechanisms that regulate
DNA methylation are involved in synaptic plasticity, learning, and
memory (Sananbenesi and Fischer, 2009). DNA is inherently sta-
ble, compared with RNA, thus development of biomarkers based
on DNA provide an attractive potential. Additionally, since mod-
ifications in DNA methylation can potentially be reversed – by
de-methylating or methylating agents – understanding the role
of DNA methylation in PTSD has the potential to fuel novel
approaches to PTSD treatment.
CONCLUSION
We evaluated DNA methylation from serum as a potential bio-
marker for PTSD. In this exploratory study of deployed personnel,
comparing those with PTSD and those who did not develop PTSD,
the latter had reduced %5-mC levels of H19 and IL18 after deploy-
ment and elevated levels of IL18 after deployment. Additionally,
pre-deployment the people who later became cases had lower levels
of IL18 %5-mC compared with controls. Whether these are mark-
ers of vulnerability or resilience is a matter of speculation, but
because of the high incidence of PTSD, it is important to study
these patterns further.
ACKNOWLEDGMENTS
The authors declare that there are no competing financial inter-
ests in relation to the work presented here. This study was funded
by a Congressionally Directed Medical Research Program Grant,
W81XWH-08-2-0053. Andrea Baccarelli received support from
the NIEHS-HSPH Center for Environmental Health New Investi-
gator Fund (P30ES000002); Zygmunt Galdzicki received support
from Air Force Medical Support Agency I-12-088.
DISCLAIMERS
The views expressed in this scientific paper are those of the
author(s) and do not reflect the official policy or position of the
U.S. government or the Department of Defense.
AUTHORS CONTRIBUTION
Jennifer A. Rusiecki was the PI of the study and conceived the
original idea, designed the study, managed the study, and directed
the data analysis and interpretation. Celia Byrne was involved in
the interpretation of the study pertaining to epidemiologic fac-
tors. Zygmunt Galdzicki was involved in the interpretation of the
study pertaining to cytokines and other genes. Vasantha Srikan-
tan was involved in the study design and initial lab preparation
of the samples. Ligong Chen carried out all statistical analyses.
Matthew Poulin carried out the measurement of methylation and
was involved in the interpretation of the results. Liying Yan car-
ried out the measurement of methylation and was involved in the
interpretation of the results. Andrea Baccarelli was involved in the
original study design and provided expertise throughout the entire
project and was involved in the interpretation of the findings. All
authors read and approved the final manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Molecular_Psychiatry/10.
3389/fpsyt.2013.00056/abstract
Table S1 | Generalized linear models for investigating the adjusted means∗
and differences between controls pre- and post-deployment and cases pre-
and post-deployment.
Table S2 | Generalized linear models investigating the adjusted means∗ and
differences between cases and controls, pre-deployment and
post-deployment.
REFERENCES
Agis-Balboa, R. C., Arcos-Diaz,
D., Wittnam, J., Govindarajan,
N., Blom, K., Burkhardt, S.,
et al. (2011). A hippocampal
insulin-growth factor 2 path-
way regulates the extinction of
fear memories. EMBO J. 30,
4071–4083. doi:10.1038/emboj.20
11.293
Alboni, S., Cervia, D., Sugama,
S., and Conti, B. (2010).
Interleukin 18 in the CNS. J.
Neuroinflammation 7, 9. doi:10.
1186/1742-2094-7-9
Anderson, G., and Rodriguez, M.
(2011). Multiple sclerosis, seizures,
and antiepileptics: role of IL-18,
IDO, and melatonin. Eur. J. Neu-
rol. 18, 680–685. doi:10.1111/j.1468-
1331.2010.03257.x
Anker, P., Mulcahy, H., Chen, X. Q.,
and Stroun, M. (1999). Detec-
tion of circulating tumour DNA in
the blood (plasma/serum) of can-
cer patients. Cancer Metastasis Rev.
18, 65–73. doi:10.1023/A:100626031
9913
Armed Forces Health Surveillance
Center. (2011). Available at: http:
//www.afhsc.mil/viewDocument?
file=CaseDefs/Web_12_MENTAL%
20HEALTH_MAR11.pdf
Atamaniuk, J., Hsiao, Y. Y., Mustak, M.,
Bernhard, D., Erlacher, L., Fodinger,
M., et al. (2011). Analysing cell-free
plasma DNA and SLE disease activ-
ity. Eur. J. Clin. Invest. 41, 579–583.
doi:10.1111/j.1365-2362.2010.02
435.x
Bannert, N., Vollhardt, K., Asomuddi-
nov, B., Haag, M., Konig, H., Nor-
ley, S., et al. (2003). PDZ domain-
mediated interaction of interleukin-
16 precursor proteins with myosin
phosphatase targeting subunits. J.
Biol. Chem. 278, 42190–42199.
doi:10.1074/jbc.M306669200
Frontiers in Psychiatry | Molecular Psychiatry June 2013 | Volume 4 | Article 56 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rusiecki et al. PTSD and DNA methylation
Bossu, P., Ciaramella, A., Salani, F.,
Vanni, D., Palladino, I., Caltagirone,
C., et al. (2010). Interleukin-
18, from neuroinflammation
to Alzheimer’s disease. Curr.
Pharm. Des. 16, 4213–4224.
doi:10.2174/138161210794519147
Breslau, N. (2001). The epidemiology of
posttraumatic stress disorder: what
is the extent of the problem? J. Clin.
Psychiatry 62, 16–22.
Brown, S. E., Weaver, I. C., Meaney, M.
J., and Szyf, M. (2008). Regional-
specific global cytosine methylation
and DNA methyltransferase expres-
sion in the adult rat hippocam-
pus. Neurosci. Lett. 440, 49–53.
doi:10.1016/j.neulet.2008.05.028
Cruikshank, W., and Little, F. (2008).
lnterleukin-16: the ins and outs of
regulating T-cell activation. Crit.
Rev. Immunol. 28, 467–483. doi:10.
1615/CritRevImmunol.v28.i6.10
Cunningham, M. D., Kassis, J.
A., and Pfeifer, K. (2010).
Chromatin modifiers, cogni-
tive disorders, and imprinted
genes. Dev. Cell 18, 169–170.
doi:10.1016/j.devcel.2010.01.012
Fenech, M. (2001). The role of folic
acid and Vitamin B12 in genomic
stability of human cells. Mutat.
Res. 475, 57–67. doi:10.1016/S0027-
5107(01)00069-0
Feng, J., and Fan, G. (2009). The role
of DNA methylation in the cen-
tral nervous system and neuropsy-
chiatric disorders. Int. Rev. Neuro-
biol. 89, 67–84. doi:10.1016/S0074-
7742(09)89004-1
Fu, V. X., Schwarze, S. R., Kenowski, M.
L., Leblanc, S., Svaren, J., and Jar-
rard, D. F. (2004). A loss of insulin-
like growth factor-2 imprinting
is modulated by CCCTC-binding
factor down-regulation at senes-
cence in human epithelial cells.
J. Biol. Chem. 279, 52218–52226.
doi:10.1074/jbc.M405015200
Gavin, D. P., and Sharma, R. P. (2010).
Histone modifications, DNA
methylation, and schizophrenia.
Neurosci. Biobehav. Rev. 34, 882–888.
doi:10.1016/j.neubiorev.2009.
10.010
Goebel, G., Zitt, M., Zitt, M., and Muller,
H. M. (2005). Circulating nucleic
acids in plasma or serum (CNAPS)
as prognostic and predictive mark-
ers in patients with solid neoplasias.
Dis. Markers 21, 105–117.
Gormally, E., Caboux, E., Vineis, P.,
and Hainaut, P. (2007). Circulating
free DNA in plasma or serum as
biomarker of carcinogenesis: prac-
tical aspects and biological signif-
icance. Mutat. Res. 635, 105–117.
doi:10.1016/j.mrrev.2006.11.002
Gu, Y., Dee, C. M., and Shen, J. (2011).
Interaction of free radicals, matrix
metalloproteinases and caveolin-1
impacts blood-brain barrier perme-
ability. Front. Biosci. (Schol. Ed.) 3,
1216–1231. doi:10.2741/222
Herry, C., Ciocchi, S., Senn, V.,
Demmou, L., Muller, C., and
Luthi, A. (2008). Switching on
and off fear by distinct neu-
ronal circuits. Nature 454, 600–606.
doi:10.1038/nature07166
Hoge, C., Castro, C., Messer, S. C.,
McGurk, D., Cotting, D., and Koff-
man, R. (2004). Combat duty in
Iraq and Afghanistan, mental health
problems, and barriers to care. N.
Engl. J. Med. 351, 13–22.
Hoge, E. A., Brandstetter, K., Moshier,
S., Pollack, M. H., Wong, K. K., and
Simon, N. M. (2009). Broad spec-
trum of cytokine abnormalities in
panic disorder and posttraumatic
stress disorder. Depress. Anxiety 26,
447–455. doi:10.1002/da.20564
Iwamoto, K., and Kato, T. (2009).
Epigenetic profiling in schizophre-
nia and major mental disorders.
Neuropsychobiology 60, 5–11.
doi:10.1159/000234811
Joels, M., Krugers, H., and Karst, H.
(2008). Stress-induced changes in
hippocampal function. Prog. Brain
Res. 167, 3–15. doi:10.1016/S0079-
6123(07)67001-0
Jung, H. K., Ryu, H. J., Kim, M. J.,
Kim, W. I., Choi, H. K., Choi, H.
C., et al. (2012). Interleukin-18
attenuates disruption of brain-
blood barrier induced by status
epilepticus within the rat piriform
cortex in interferon-gamma inde-
pendent pathway. Brain Res. 1447,
126–134. doi:10.1016/j.brainres.
2012.01.057
Kawamura, N., Kim, Y., and Asukai,
N. (2001). Suppression of cellular
immunity in men with a past history
of posttraumatic stress disorder. Am.
J. Psychiatry 158, 484–486.
Keniry, A., Oxley, D., Monnier, P.,
Kyba, M., Dandolo, L., Smits, G.,
et al. (2012). The H19 lincRNA is
a developmental reservoir of miR-
675 that suppresses growth and
Igf1r. Nat. Cell Biol. 14, 659–665.
doi:10.1038/ncb2521
Kessler, R. C., David, C. G., and Kendler,
K. S. (1997). Childhood adversity
and adult psychiatric disorder in
the US National Comorbidity Sur-
vey. Psychol. Med. 27, 1101–1119.
doi:10.1017/S0033291797005588
Kessler, R. C., McGonagle, D. A., Zhao,
S., Nelson, C. B., Hughes, M., Eshel-
man, S., et al. (1994). Lifetime and
12-month prevalence of DSM-IIIR
psychiatric disorders in the United
States: results from the national
comorbidity survey. Arch. Gen. Psy-
chiatry 51, 8–19.
Kessler, R. C., Sonega, A., Bromet,
E., Hughes, M., and Nelson, C.
B. (1995). Posttraumatic stress dis-
order in the national comorbid-
ity survey. Arch. Gen. Psychia-
try 52, 1048–1060. doi:10.1001/
archpsyc.1995.03950240066012
Koenen, K. C., Uddin, M., Chang, S.
C., Aiello, A. E., Wildman, D. E.,
Goldmann, E., et al. (2011). SLC6A4
methylation modifies the effect of
the number of traumatic events on
risk for posttraumatic stress disor-
der. Depress. Anxiety 28, 639–647.
doi:10.1002/da.20825
Kuratomi, G., Iwamoto, K., Bundo,
M., Kusumi, I., Kato, N., Iwata,
N., et al. (2008). Aberrant DNA
methylation associated with
bipolar disorder identified from
discordant monozygotic twins.
Mol. Psychiatry . 13, 429–441.
doi:10.1038/sj.mp.4002001
Kurschner, C., and Yuzaki, M.
(1999). Neuronal interleukin-
16 (NIL-16): a dual function PDZ
domain protein. J. Neurosci. 19,
7770–7780.
Ladd-Acosta, C., Pevsner, J., Sabun-
ciyan, S., Yolken, R. H., Webster, M.
J., Dinkins, T., et al. (2007). DNA
methylation signatures within the
human brain. Am. J. Hum. Genet. 81,
1304–1315. doi:10.1086/524110
Maes, M., Lin, A. H., Delmeire, L.,
Van Gastel, A., Kenis, G., De
Jongh, R., et al. (1999). Elevated
serum interleukin-6 (IL-6) and IL-
6 receptor concentrations in post-
traumatic stress disorder follow-
ing accidental man-made trau-
matic events. Biol. Psychiatry 45,
833–839.
Mill, J., and Petronis, A. (2007). Mol-
ecular studies of major depressive
disorder: the epigenetic perspec-
tive. Mol. Psychiatry 12, 799–814.
doi:10.1038/sj.mp.4001992
Miller, C. A., and Sweatt, J. D.
(2007). Covalent modification
of DNA regulates memory for-
mation. Neuron 53, 857–869.
doi:10.1016/j.neuron.2007.02.022
Nowotny, B., Cavka, M., Herder, C., Lof-
fler, H., Poschen, U., Joksimovic, L.,
et al. (2010). Effects of acute psy-
chological stress on glucose metab-
olism and subclinical inflamma-
tion in patients with post-traumatic
stress disorder. Horm. Metab. Res. 42,
746–753.
Oliveira, N. F., Damm, G. R., Andia,
D. C., Salmon, C., Nociti, F. H.
Jr., Line, S. R., et al. (2009). DNA
methylation status of the IL8 gene
promoter in oral cells of smok-
ers and non-smokers with chronic
periodontitis. J. Clin. Periodon-
tol. 36, 719–725. doi:10.1111/j.1600-
051X.2009.01446.x
Piyathilake, C. J., and Johanning, G.
L. (2002). Cellular vitamins, DNA
methylation and cancer risk. J. Nutr.
132, 2340S–2344S.
Ressler, K. J., Mercer, K. B., Bradley, B.,
Jovanovic, T., Mahan, A., Kerley, K.,
et al. (2011). Post-traumatic stress
disorder is associated with PACAP
and the PAC1 receptor. Nature 470,
492–497. doi:10.1038/nature09856
Rhodes, A., Wort, S. J., Thomas, H.,
Collinson, P., and Bennett, E. D.
(2006). Plasma DNA concentration
as a predictor of mortality and sepsis
in critically ill patients. Crit. Care 10,
R60. doi:10.1186/cc4894
Rostene, W., Dansereau, M. A., Gode-
froy, D., Van Steenwinckel, J.,
Reaux-Le Goazigo, A., Melik-
Parsadaniantz, S., et al. (2011).
Neurochemokines: a menage a
trois providing new insights on the
functions of chemokines in the cen-
tral nervous system. J. Neurochem.
118, 680–694. doi:10.1111/j.1471-
4159.2011.07371.x
Rusiecki, J. A., Chen, L., Srikantan,
V., Zhang, L., Yan, L., Polin, M.
L., et al. (2012). DNA methyla-
tion in repetitive elements and post-
traumatic stress disorder: a case-
control study of US military ser-
vice members. Epigenomics 4, 29–40.
doi:10.2217/epi.11.116
Ryu, H. J., Kim, J. E., Kim, M. J., Kwon,
H. J., Suh, S. W., Song, H. K., et
al. (2010). The protective effects
of interleukin-18 and interferon-
gamma on neuronal damages in
the rat hippocampus following
status epilepticus. Neuroscience 170,
711–721. doi:10.1016/j.neuroscience.
2010.07.048
Sananbenesi, F., and Fischer, A. (2009).
The epigenetic bottleneck of neu-
rodegenerative and psychiatric dis-
eases. Biol. Chem. 390, 1145–1153.
doi:10.1515/BC.2009.131
Sarapas, C., Cai, G., Bierer, L. M.,
Golier, J. A., Galea, S., Ising,
M., et al. (2011). Genetic mark-
ers for PTSD risk and resilience
among survivors of the World
Trade Center attacks. Dis. Mark-
ers 30, 101–110. doi:10.3233/DMA-
2011-0764
SAS Institute Inc. (2008). SAS 9.2. Cary,
NC: SAS Institute.
Schiavone, S., Jaquet, V., Trabace, L.,
and Krause, K. H. (2013). Severe
life stress and oxidative stress in
the brain: from animal models
to human pathology. Antioxid.
www.frontiersin.org June 2013 | Volume 4 | Article 56 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rusiecki et al. PTSD and DNA methylation
Redox Signal. 18, 1475–1490.
doi:10.1089/ars.2012.4720
Schwab, J. M., Schluesener, H. J., Seid,
K., and Meyermann, R. (2001).
IL-16 is differentially expressed in
the developing human fetal brain
by microglial cells in zones of
neuropoesis. Int. J. Dev. Neurosci.
19, 93–100. doi:10.1016/S0736-
5748(00)00063-0
Segman, R., Shefi, N., Goltser-Dubner,
T., Friedman, N., Kaminski, N.,
and Shalev, A. (2005). Peripheral
blood mononuclear cell gene expres-
sion profiles identify emergent post-
traumatic stress disorder among
trauma survivors. Mol. Psychiatry
10, 500–513.
Seitz, H. K., and Stickel, F. (2007).
Molecular mechanisms of
alcohol-mediated carcinogene-
sis. Nat. Rev. Cancer 7, 599–612.
doi:10.1038/nrc2191
Semple, B. D., Kossmann, T., and
Morganti-Kossmann, M. C.
(2010). Role of chemokines in
CNS health and pathology: a
focus on the CCL2/CCR2 and
CXCL8/CXCR2 networks. J. Cereb.
Blood Flow Metab. 30, 459–473.
doi:10.1038/jcbfm.2009.240
Shimabukuro, M., Sasaki, T., Imamura,
A., Tsujita, T., Fuke, C., Umekage,
T., et al. (2007). Global hypomethy-
lation of peripheral leukocyte
DNA in male patients with schiz-
ophrenia: a potential link between
epigenetics and schizophrenia.
J. Psychiatr. Res. 41, 1042–1046.
doi:10.1016/j.jpsychires.2006.
08.006
Smith, A. K., Conneely, K. N., Kilaru,
V., Mercer, K. B., Weiss, T. E.,
Bradley, B., et al. (2011). Differen-
tial immune system DNA methy-
lation and cytokine regulation in
post-traumatic stress disorder. Am. J.
Med. Genet. B Neuropsychiatr. Genet.
156B, 700–708.
Spivak, B., Shohat, B., Mester, R.,
Avraham, S., Gil-Ad, I., Bleich,
A., et al. (1997). Elevated lev-
els of serum interleukin-1 beta
in combat-related posttraumatic
stress disorder. Biol. Psychiatry
42, 345–348. doi:10.1016/S0006-
3223(96)00375-7
Stroun, M., Lyautey, J., Lederrey, C.,
Olson-Sand, A., and Anker, P.
(2001). About the possible ori-
gin and mechanism of circulat-
ing DNA apoptosis and active
DNA release. Clin. Chim. Acta
313, 139–142. doi:10.1016/S0009-
8981(01)00665-9
Sutherland, A. G., Alexander, D.
A., and Hutchison, J. D. (2003).
Disturbance of pro-inflammatory
cytokines in post-traumatic psy-
chopathology. Cytokine 24, 219–225.
doi:10.1016/j.cyto.2003.09.004
Tamura, Y., Kunugi, H., Ohashi, J.,
and Hohjoh, H. (2007). Epige-
netic aberration of the human
REELIN gene in psychiatric disor-
ders. Mol. Psychiatry 12, 593–600.
doi:10.1038/sj.mp.4001965
Thomas, J. L., Wilk, J. E., Riviere, L.
A., McGurk, D., Castro, C. A., and
Hoge, C. W. (2010). Prevalence of
mental health problems and func-
tional impairment among active
component and National Guard sol-
diers 3 and 12 months following
combat in Iraq. Arch. Gen. Psy-
chiatry 67, 614–623. doi:10.1001/
archgenpsychiatry.2010.54
Toh, Y., Oki, E., Ohgaki, K., Sakamoto,
Y., Ito, S., Egashira, A., et al. (2010).
Alcohol drinking, cigarette smok-
ing, and the development of squa-
mous cell carcinoma of the esopha-
gus: molecular mechanisms of car-
cinogenesis. Int. J. Clin. Oncol.
15, 135–144. doi:10.1007/s10147-
010-0057-6
Torres-Aleman, I. (2010). Toward a
comprehensive neurobiology of
IGF-I. Dev. Neurobiol. 70, 384–396.
doi:10.1002/dneu.20778
Trollope, A. F., Gutierrez-Mecinas,
M., Mifsud, K. R., Collins, A.,
Saunderson, E. A., and Reul, J. M.
(2012). Stress, epigenetic control
of gene expression and memory
formation. Exp. Neurol. 233, 3–11.
doi:10.1016/j.expneurol.2011.03.022
Uddin, M., Aiello, A., Wildman, D.,
Koenen, K., Pawelec, G., de los
Santos, R., et al. (2010). Epi-
genetic and immune function
profiles associated with posttrau-
matic stress disorder. Proc. Natl.
Acad. Sci. U.S.A. 107, 9470–9475.
doi:10.1073/pnas.0910794107
Uddin, M., Galea, S., Chang, S. C.,Aiello,
A. E., Wildman, D. E., de Los Santos,
R., et al. (2011). Gene expression and
methylation signatures of MAN2C1
are associated with PTSD. Dis. Mark-
ers 30, 111–121. doi:10.3233/DMA-
2011-0750
van Zuiden, M., Gueze, E., Wille-
men, H., Vermetten, E., Maas,
M., Heijnen, C., et al. (2011).
Pre-existing high glucocorticoid
receptor number predicting devel-
opment of posttraumatic stress
symptoms after military deploy-
ment. Am. J. Psychiatry 168, 89–96.
doi:10.1176/appi.ajp.2010.10050706
von Kanel, R., Hepp, U., Kraemer,
B., Traber, R., Keel, M., Mica,
L., et al. (2007). Evidence for
low-grade systemic proinflamma-
tory activity in patients with post-
traumatic stress disorder. J. Psychi-
atr. Res. 41, 744–752.
Zhu, Z. Z., Hou, L., Bollati, V., Taran-
tini, L., Marinelli, B., Cantone, L.,
et al. (2012). Predictors of global
methylation levels in blood DNA of
healthy subjects: a combined analy-
sis. Int. J. Epidemiol. 41, 126–139.
doi:10.1093/ije/dyq154
Ziegler, A. N., Schneider, J. S., Qin,
M., Tyler, W. A., Pintar, J. E.,
Fraidenraich, D., et al. (2012).
Igf-ii promotes stemness of neural
restricted precursors. Stem Cells 30,
1265–1276. doi:10.1002/stem.1095
Zieker, J., Zieker, D., Jatzko, A., Diet-
zsch, J., Nieselt, K., Schmitt, A.,
et al. (2007). Differential gene
expression in peripheral blood
of patients suffering from post-
traumatic stress disorder, letter to
the editor. Mol. Psychiatry 12,
116–119.
Zovkic, I. B., and Sweatt, J. D. (2013).
Epigenetic mechanisms in learned
fear: implications for PTSD. Neu-
ropsychopharmacology 38, 77–93.
doi:10.1038/npp.2012.79
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 07 March 2013; accepted: 02
June 2013; published online: 24 June
2013.
Citation: Rusiecki JA, Byrne C, Galdzicki
Z, Srikantan V, Chen L, Poulin M, Yan L
and Baccarelli A (2013) PTSD and DNA
methylation in select immune function
gene promoter regions: a repeated mea-
sures case-control study of U.S. military
service members. Front. Psychiatry 4:56.
doi: 10.3389/fpsyt.2013.00056
This article was submitted to Frontiers
in Molecular Psychiatry, a specialty of
Frontiers in Psychiatry.
Copyright © 2013 The authors do not
own copyright as US Federal Employees.
This is an open-access article distributed
under the terms of the Creative Com-
mons Attribution License, which per-
mits use, distribution and reproduction in
other forums, provided the source is cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Psychiatry | Molecular Psychiatry June 2013 | Volume 4 | Article 56 | 12
